ICIs are monoclonal antibodies (mAbs) directed against ICs expressed by immune cells that prevent the inhibition of anti-cancer T cells, primarily CD8 T cells, enhancing the specific responses to tumors. The gene discussed is CD8A; the disease is cancer.